Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Accounts Payables: 2020-2024

Historic Accounts Payables for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $2.4 million.

  • Mereo BioPharma Group's Accounts Payables fell 49.71% to $879,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $879,000, marking a year-over-year decrease of 49.71%. This contributed to the annual value of $2.4 million for FY2024, which is 4.01% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Accounts Payables stood at $2.4 million for FY2024, which was up 4.01% from $2.3 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Accounts Payables registered a high of $4.3 million during FY2020, and its lowest value of $2.3 million during FY2023.
  • In the last 3 years, Mereo BioPharma Group's Accounts Payables had a median value of $2.4 million in 2024 and averaged $2.8 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Accounts Payables crashed by 32.82% in 2023, and later grew by 4.01% in 2024.
  • Mereo BioPharma Group's Accounts Payables (Yearly) stood at $4.3 million in 2020, then dropped by 21.29% to $3.4 million in 2021, then grew by 3.66% to $3.5 million in 2022, then plummeted by 32.82% to $2.3 million in 2023, then climbed by 4.01% to $2.4 million in 2024.